Leaders | Poor prescription

America’s moves against Chinese biotech will hurt patients at home

The motives behind the BIOSECURE act are muddy

Judge looking through mallet shaped microscope
Illustration: Travis Constantine

America’s crackdown on Chinese trade is broadening. On the campaign trail on April 17th President Joe Biden proposed tripling tariffs on steel imports, citing China’s unfair trade practices. Having choked off China’s access to advanced semiconductors and moved to ban TikTok, a Chinese-owned social-media app, lawmakers are eyeing a new target: biotechnology. The biosecure act, which has bipartisan support in Congress, proposes to end government contracts for firms that count Chinese biotech companies as clients or suppliers. American officials have previously said they want to guard a “small yard” of sensitive technologies with a “high fence”. This bill illustrates that the yard is getting bigger, with sorry consequences for American consumers.

Explore more

This article appeared in the Leaders section of the print edition under the headline “Poor prescription”

Reasons to be cheerful about Generation Z

From the April 20th 2024 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Leaders

Germany’s failure to lead the EU is becoming a problem

A weak chancellor and coalition rows are to blame

How to ensure Africa is not left behind by the AI revolution

Weak digital infrastructure is holding the continent back


A global gold rush is changing sport

Fans may be cooling on the Olympics, but elsewhere technology is transforming how sport is watched


Can Kamala Harris win?

Joe Biden’s vice-president has an extraordinary opportunity. But she also has a mountain to climb

MAGA Republicans are wrong to seek a cheaper dollar

It is hard to cast America as a victim of the global financial system

Joe Biden has given Democrats a second chance to win the White House

If they are not to squander it, they must have a proper contest